




# KRAS *therascreen*<sup>®</sup>

## Unlocking Targeted Treatment with KRAS Mutation Analysis

The KRAS therascreen test represents a significant advancement in oncology, targeting mutations within the KRAS oncogene prevalent in various human cancers. Specifically designed to identify mutations associated with resistance to EGFR inhibitor therapies in metastatic colorectal cancer, this test is pivotal for approximately 40% of patients. **Rapid results from our assay are typically available within 48-72 hours.**



### Key Benefits:

- Rapid Results: Delivering actionable insights within 48 hours, supporting swift clinical decisions.
- Minimal Sample Requirement: Leveraging quantitative methodology for efficient testing.
- FDA Approved: Validated rigorously to ensure reliability and accuracy.
- Aligned with NCCN Guidelines: Part of a comprehensive approach to oncology care.

### Optimizing Patient Outcomes:

The KRAS precision medicine test is customized to an individual's genetic blueprint, holds immense promise for enhancing treatment effectiveness and improving patient outcomes. By harnessing genetic data, healthcare providers can finely tune interventions and therapies to match the distinct genetic traits of each patient, resulting in actionable insights delivered in a matter of days rather than weeks.

### Clinical Utility

**FDA Approved**  
**Aligned with NCCN Guidelines**  
**Rapid Results**  
**Minimal Sample Requirements**

**Personalized Treatment**  
**Precision Medicine**  
**Early Detection**

Jones RP, Sutton PA, et. al. 2017 Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. Mar 28;116(7):923-929

For more information, please contact us at: [cs@emeritusdx.com](mailto:cs@emeritusdx.com)

**EmeritusDX**  
Together, We Save Lives

800.959.2846

[www.emeritusdx.com](http://www.emeritusdx.com)



EDX-KRA 0224